drugset / Trial / NCT04522817
CLBS119 for Repair of COVID-19 Induced Pulmonary Damage
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial will explore the safety and potential efficacy of CLBS119 for the repair of COVID-19 induced pulmonary damage in adults.
Timeline
- Start
- 2020-10-05
- Primary completion
- 2021-05
- Completion
- 2021-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells | Unknown | — | — |